In this large, real-world, propensity-matched analysis of non-diabetic patients with overactive bladder, concurrent use of GLP-1 receptor agonists was associated with a lower risk of urinary retention and UTI following BTX-A treatment. Here, GLP1R is linked to overactive bladder.